glutathione and multiple myeloma Lipid metabolic vulnerabilities of | Clinical Experimental Medicine Review on Bortezomib Resistance in
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma Blood Cancer Journal Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance Frontiers Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment
Pay in 4 interest-free payments of $6.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



